Curis (NASDAQ:CRIS) Shares to Reverse Split on Monday, July 6th

Shares of Curis, Inc. (NASDAQ:CRIS) are going to reverse split on Monday, July 6th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, July 5th.

Curis Stock Down 17.9%

CRIS traded down $0.08 during trading hours on Thursday, hitting $0.35. 2,359,126 shares of the company’s stock were exchanged, compared to its average volume of 1,895,807. The stock has a market cap of $13.51 million, a price-to-earnings ratio of -0.29 and a beta of 3.08. Curis has a 1-year low of $0.18 and a 1-year high of $2.01. The stock’s 50-day moving average is $0.49 and its two-hundred day moving average is $0.75.

Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.92). On average, equities research analysts anticipate that Curis will post -1.27 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CRIS. Zacks Research downgraded Curis from a “hold” rating to a “strong sell” rating in a research note on Friday, May 22nd. HC Wainwright reiterated a “buy” rating and set a $17.00 price objective on shares of Curis in a research note on Friday, March 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research note on Monday, April 20th. Finally, Wall Street Zen upgraded shares of Curis to a “hold” rating in a report on Saturday, March 28th. One investment analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, Curis currently has a consensus rating of “Reduce” and an average target price of $17.00.

Institutional Investors Weigh In On Curis

Hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC boosted its position in Curis by 71.8% during the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 10,586 shares during the period. XTX Topco Ltd bought a new position in shares of Curis in the fourth quarter valued at about $26,000. Squarepoint Ops LLC raised its position in shares of Curis by 17.9% in the third quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 8,973 shares during the period. Focused Wealth Management Inc lifted its stake in shares of Curis by 83.4% during the 1st quarter. Focused Wealth Management Inc now owns 109,746 shares of the biotechnology company’s stock worth $60,000 after buying an additional 49,900 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in shares of Curis by 2,883,237.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after buying an additional 230,659 shares during the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.